代表性成果 (论文/专利/专著等) |
1. Chen C, Sui X, Ning H, Sun Y, Du J, Chen X, Zhou X, Chen G, Shen W, Pang L, Zhou X, Shi R, Li W, Wang H, Zhao W, Zhai W, Qi Y, Wu Y*, Gao Y*. Identification of natural product 3, 5-diiodotyrosine as APOBEC3B inhibitor to prevent somatic mutation accumulation and cancer progression. J Immunother Cancer. 2022 Nov;10(11):e005503. (TOP一区,IF: 12.485) 2. Sui X#, Chen C#, Zhou X#, Wen X#, Shi C, Chen G, Liu J, He Z, Yao Y, Li Y*, Gao Y*. Integrative analysis of bulk and single-cell gene expression profiles to identify tumor-associated macrophage-derived CCL18 as a therapeutic target of esophageal squamous cell carcinoma. J Exp Clin Cancer Res. 2023 Feb 27;42(1):51. (TOP一区,IF: 12.658) 3. Sun Y, Qian Y, Chen C, Wang H, Zhou X, Zhai W, Qiu L, Zhou X, Ning H, Zhao Y, Shi C, Han L, Qi Y, Wu Y*, Gao Y*. Extracellular vesicle IL-32 promotes the M2 macrophage polarization and metastasis of esophageal squamous cell carcinoma via FAK/STAT3 pathway. J Exp Clin Cancer Res. 2022, 41(1):145. (TOP一区, IF: 12.658) 4. Shen W, Zhai W, Zhou X, Chen C, Sui X, Tian W, Dong Q, Jin S, Wu Y, Chen G, Qiu L, Gao Y*. Discovery of a novel dual-targeting D-peptide to block CD24/Siglec-10 and PD-1/PD-L1 interaction and synergize with radiotherapy for cancer immunotherapy. J Immunother Cancer. 2023 Jun;11(6): e007068. (TOP一区, IF: 12.485) 5. Wang H, Sun Y, Zhou X, Chen C, Jiao L, Li W, Gou S, Li Y, Du J, Chen G, Zhai W, Wu Y, Qi Y, Gao Y*. CD47/SIRPα blocking peptide identification and synergistic effect with irradiation for cancer immunotherapy. J Immunother Cancer. 2020 Oct;8(2):e000905. (TOP一区,IF: 12.485) 6. Zhou X, Du J, Wang H, Chen C, Jiao L, Cheng X, Zhou X, Chen S, Gou S, Zhao W, Zhai W, Chen J*, Gao Y*. Repositioning liothyronine for cancer immunotherapy by blocking the interaction of immune checkpoint TIGIT/PVR. Cell Commun Signal. 2020 Sep 7;18(1):142. (二区, IF: 7.525) 7. Zhou X, Du J, Zhou X, Niu X, Li W, Chen C, Lv S, Wu A, Gou S, Sun Y, Zhai W, Qiu L, Qi Y, Zhao W*, Gao Y*. Computer-aided design of PVR mutants with enhanced binding affinity to TIGIT. Cell Commun Signal. 2021 Feb 8;19(1):12. (二区,IF: 7.525) 8. 高艳锋; 吴亚红; 陈春霞; 宁浩明; 翟文杰; 祁元明; APOBEC3B抑制剂及其应用, 2023-10-27, 中国, ZL 2021 1 1223018.4 (国家发明专利) |